Kiniksa Pharmaceuticals Inc. and Scholar Rock Holding Corp. completed their journeys to the public markets, as Aptinyx Inc. – fresh off completion of its option deal with Allergan plc for a candidate to treat major depressive disorder – sought to follow in their footsteps.